Andrographolide 1, a diterpene lactone of Andrographis paniculata, displays in vitro and in vivo antitumor activity against breast cancer models and mouse myeloid leukemia (M1) cells. In the present study, we report the semi-synthesis of andrographolide derivatives and their in vitro activity against A549 (ATCC) (NSCL cancer) cell line. Amongst the derivatives tested, compounds 3-5 displayed maximum activity, with IC 50 values of 22-31 μg/mL.
Andrographolide (1), a major bioactive component of the plant, is a bicyclic diterpene lactone, which contains three hydroxy groups at C-3, C-14 and C-19 [3] [4] [5] . The compound has multiple pharmacological properties, such as antihepatotoxic, anti-HIV, immunostimulant, anticancer and hypoglycemic activities [6] [7] [8] . Recent studies have indicated that andrographolide (1) has the potential to be developed as an anticancer chemotherapeutic agent [8] . Andrographolide and congeners displayed potent cell differentiation-inducing activity on mouse myeloid leukemia (M1) cells. The anticancer activity of andrographolide is exerted through blockage of cell cycle progression by the decrease in cyclin-dependant kinase (CDK 4 ) expression.
Therefore, evaluation of many semi-synthetic derivatives of andrographolide as antitumor agents has been reported [9] . We report herein the semi-synthesis of derivatives of andrographolide and evaluation of their anticancer activity against A549 ATCC (NSCL cancer) cell lines.
The benzylidene derivatives 2-6 of andrographolide ( Figure 1 ) were synthesized from andrographolide through reaction with substituted benzaldehyde in the presence of amberlyst-15 ® . The selective esterification of the C-19 hydroxy group was achieved by reaction of 1 with formic acid in the presence of amberlyst-15 ® and tosyl chloride/pyridine to give C-19 esters 7 and 8, respectively. The reaction of 1 with p-toluenesulfonylisocyanate gave C-19 tosylaminocarbonyl derivative 9.
Andrographolide and semisynthetic derivatives 2-9 were evaluated for anticancer activity against the A549 (ATCC) cell line using the SRB assay, which provides a sensitive measure of drug-induced cytotoxicity [10] .
The percent inhibition of cell growth after 24 and 48 h exposure are given in Table 1 .
These findings suggest that the 3,19-benzylidene derivatives 3-5 display better antitumor activity (with IC 50 values of 22-31 μg/mL) against the A549 cell line with 48 h exposure than other benzylidene and C-19 ester derivatives prepared in the present study. Taken together, our experimental data may justify further investigation of the chemotherapeutic potential of these semi-synthetic derivatives of andrographolide.
Experimental

General procedure for synthesis of 3, 19-(benzylidene)-derivatives of andrographolide (2-6):
A mixture of andrographolide (1) (100 mg, 0.285 mmol), substituted benzaldehyde (0.855 mmol) and activated Amberlyst-15 ® (50 mg) in dry 1,4-dioxane (4 mL) was refluxed for 5 h. The reaction mixture was cooled and filtered to remove the catalyst. The organic layer was evaporated in vacuo and the residue was subjected to column chromatography (silica gel, elution with light petroleum (60-80°C)/ ethyl acetate, 80:20) to give benzylidine derivatives 2-6.
3, 19-(4'-Methoxybenzylidene)-andrographolide (2)
Yield 130 mg (50% 
Anti-tumor activity assay (SRB assay) in vitro [10]:
Human A549 (ATCC) cell lines were grown in RPMI 1640 medium containing 10% fetal bovine serum and 2 mM L-glutamine.
The cells were inoculated into 96 well microtiter plates in 90 µL medium and were incubated at 37 • C, 5% CO 2 , 95% air and 100% relative humidity for 24 h prior to addition of experimental compounds. After 24 h, one 96 well plate containing 5x10 3 cells/well was fixed in situ with TCA to represent a measurement of the cell population at the time of drug addition (Tz). The compounds 1-9 were initially solubilized in dimethyl sulfoxide at 10 mg/mL and diluted to 1 mg/mL using water and stored frozen prior to use. At the time of compound addition, an aliquot of frozen concentrate (1 mg/mL) was thawed and diluted to 100 µg/mL, 200 µg/mL, 400 µg/mL and 800 µg/mL with complete medium. Aliquots of 10 µL of these different compound dilutions were added to the appropriate microtiter wells already containing 90 µL of medium, resulting in the required final drug concentration i. e. 10 µg/mL, 20 µg/mL, 40 µg/mL, 80 µg/mL.
Endpoint measurement:
After compound addition, plates were incubated under standard conditions for 24 and 48 h and the assay was terminated by the addition of cold trichloroacetic acid (TCA). Cells were fixed in situ by the gentle addition of 50 µL of cold 30% (W/V) TCA (final concentration, 10% TCA) and incubated for 60 min at 4°C. The supernatant was discarded; the plates were washed 5 times with tap water and air dried. Sulforhodamine B (SRB) solution (50 µL) at 0.4% (w/v) in 1% acetic acid was added to each of the wells, and the plates were incubated for 20 min at room temperature. After staining, unbound dye was recovered and the residual dye was removed by washing 5 times with 1% acetic acid. The plates were dried in air. Bound stain was subsequently eluted with 10 mM trizma base, and the absorbance was read on a plate reader at a wavelength of 540 nm. Adriamycin ® was kept as a positive control with the same range of concentrations as that of test compounds.
